Thrombus Imaging and Treatment Analytics in Neurology

Thrombosis Clinical Trial

— Titan  

Official title:

Thrombus Imaging and Treatment Analytics in Neurology

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05663281
• Other study ID #: 301Titan
• Status: Recruiting
• Start date: December 15, 2022
• Est. completion date: December 31, 2027

Study information

• Verified date: February 2023
• Source: Chinese PLA General Hospital
• Contact: Jinhao Lyu, M.D.
• Phone: +8615903562929
• Email: 330322990[@]qq.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In the present study, the investigators use high-resolution MR vessel wall imaging, and select patients with cerebral and cervical artery occlusion to investigate the relationship between the imaging appearance of thrombus and the various outcome of recanalization treatment.

Description:

Cerebral ischemic stroke resulting from thrombosis causes high disability and mortality. There are few biomarkers to evaluate arterial thrombophilia until now. Previous studies have demonstrated that atherosclerotic plaque rupture and erosion are major etiologies initiating thrombosis. Based on previous works targeting the role of plaque and blood flow in cerebrovascular disease, in the present study, the investigators use high-resolution MR vessel wall imaging, and select patients with cerebral and cervical artery occlusion to explore the relationship between the imaging appearance of thrombus and the various outcome of recanalization treatment. The study's objective was to solve the challenges in the mechanism of thrombus features and the outcome of recanalization therapy, thus helping improve the primary and secondary prevention of cerebrovascular disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years
• Extracranial and/or intracranial artery occlusion confirmed by angiography
• Available for magnetic resonance high-resolution vessel wall imaging
• Written informed consent obtained

Exclusion Criteria:

• Extracranial and/or intracranial artery mild to moderate stenosis
• Pregnant women
• Restenosis or occlusion after artery stenting placement

Related Conditions & MeSH terms

• Intracranial Thrombosis
• Thrombosis

Intervention

Diagnostic Test:
• thrombus imaging appearance
Imaging appearance of intracranial and/or extracranial arterial thrombus

Locations

Country	Name	City	State
China	Chinese PLA General Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Successful Recanalization	Antegrade blood flow through the recanalized portion was assessed by thrombolysis in myocardial infarction (TIMI) score or thrombolysis in cerebral infarction (TICI) score. TIMI=2 or TICI=2b was defined as successful recanalization.	1-3 Years
Primary	Ischemic Stroke Occurrence	Ischemic stroke occurrence during follow-up period which was confirmed by neuroimaging	1-3 Years
Secondary	Number of Participants with Adverse Events	hemorrhagic or ischemic stroke after recanalization treatment	1-3 Years